We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NMT Neometals Ltd

0.00 (0.0%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Neometals Ltd LSE:NMT London Ordinary Share AU000000NMT1 ORD NPV (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 10.25 28 08:00:00
Bid Price Offer Price High Price Low Price Open Price
10.00 10.50 10.25 10.25 10.25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Minrls,earths-ground,treated AUD 5k AUD -34.8M AUD -0.0629 -3.18 110.66M
Last Trade Time Trade Type Trade Size Trade Price Currency
10:15:06 O 9 10.40 GBX

Neometals (NMT) Latest News

Neometals (NMT) Discussions and Chat

Neometals Forums and Chat

Date Time Title Posts
10/7/200713:13NMT. 'Safer at the Sharp End'.7,582
29/11/200616:58NMT.....Good news soon?3
14/4/200620:46Come over to CMS Webview to recover your Losses20
07/9/200510:59NMT - Shares = 0.55p, Net Cash = 0.8p30

Add a New Thread

Neometals (NMT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Neometals (NMT) Top Chat Posts

Top Posts
Posted at 04/12/2023 08:20 by Neometals Daily Update
Neometals Ltd is listed in the Minrls,earths-ground,treated sector of the London Stock Exchange with ticker NMT. The last closing price for Neometals was 10.25p.
Neometals currently has 553,307,937 shares in issue. The market capitalisation of Neometals is £110,661,587.
Neometals has a price to earnings ratio (PE ratio) of -3.18.
This morning NMT shares opened at 10.25p
Posted at 29/10/2006 10:36 by 25october1969
Price post acquisition will as usual, in the first instance, be dictated by number of buyers and sellers, eg if those who exchange NMT shares for Volvere want to sell, then Volvere price will fall or at least not rise.

I do not know if Volvere have any interest in their share price rising in the short term so do not know is they will use PR to highlight the 25%+ increase in NAV. If they do and have firm plans for use of the NMT cash which interest the market and existing businesses are moving into profit, then who knows we may get a move upwards

Interesting that post acquisition, Merrill Lynch have 3.4%%, United Gulf Bank 4.8% and JP Morgan 6%, though possibily one of them has been selling in the market. Would hope having institutional shareholders on board might generate some city interest, who knows

With respect to the small shareholders, bear in mind that we could have a scenario where Volvere get less than 90% and say stuff it, lets just delist NMT and leave the small shareholders with shares in NMT!
Posted at 29/10/2006 08:20 by pc4900074200
Thanks 250.

I thought that you would have that covered but as they say,
you never know and theres no harm in asking. I have another
question regarding post consolidation adjustment [8174k].

Are you expecting the MM's to initially raise / drop the share price of
Volvere or hold it?

They have the price ATM under the valueation of NMT shares
given by Volvere [00:605p NMT x 3 = 01:815p].

Another thought?

At the last NMT EGM that the previous MD ran, it was stated
that there were approx. 7500 MNT shareholders and ADVFN's data
show that only around 1300 have sold. [Taking each sell as a holding +
a few from the ???].

It looks that Volvere will have many small shareholding PI.s.
post consolidation which IMO will bring some fluidity to the
share as time goes on.

It may make rivaldo happy as he may have someone to talk to
on his BB.

BTW, I'm still thinking of jumping back in. [have sent off the remaining
NMT shares I have so will be a Volvere shareholder as it is].

Posted at 26/10/2006 12:17 by 25october1969

My philosophy nowadays is that you cannot have all your eggs in one basket with the small caps, have to spread the risk in the hope that one is a multi-bagger, and the others tick along but expact one to fall drastically.

So with that in mind four shares I would mention are SAL, ELG MED and AOR.

AOR is already a multi bagger for me and has risen a further 20% in the last few weeks so have to be very confident to buy at current level. I have not sold any as I see potential for it to go much further

ELG is as far as I am aware an undiscovered share. There is a ADVFN Board but very few posts. They incorporate keyboards etc into fabrics so that if you have an IPod the controls are on your sleeve. Sounds a bit wierd and they are making big losses but do a google news search and see the recent contracts they have won. It sounds the type of company that could be ramped to hell so please do not take this as a ramp

SAL is another undiscovered one. Very little comment on it. The are effectively brokers for advertising in shopping malls. Does not sound very exciting but seem to be the dominant player and are expanding overseas. Making a profit and paying a dividend if my memory serves me corectly

MED is one where I have received a stuffing just as big as the NMT one. When the share price was in the 30/40s the board announced a placing at 20p. Price collapsed to 25p and they would not let me take part in the placing so I have been dilluted to hell as new shares of around 60% issued. There has been other bad news along the way as share price tumbled from 150 and numerous management changes. Price now 28p and placing taken up by institution who are sitting on 40% profit. I still hold and not brave enough to buy more, they are using placing proceeds to construct manufacturing facility in Germany, they make polymer organic light emitting diode (P-OLED) based microdisplays and are very good at it, they are not so good at taking the product to market.

I hold all 4. In big profit in 1, small profit in 2 and big losses in the other so have a look and make up your own mind. All are fairly illiquid so timing of buying is important as price can move rapidly on small purchases/sales
Posted at 19/9/2006 07:19 by waldron
Tue 19 Sep 2006
Printer friendly
Send to friend
Comments (0)
Volvere agreement with Clareco opens way to NMT deal

INVESTMENT firm Volvere has passed a major hurdle in its bid to buy fallen Scottish biotech star NMT, with another major shareholder indicating it will agree to a proposed offer.

Clareco, which owns 4.1 per cent of AIM-listed NMT's shares, has now given an irrevocable undertaking to accept a recommended deal made by Volvere last week.

Volvere now owns or has irrevocable agreements for 50.1 per cent of NMT's capital, meaning its offer can now be made unconditionally.

The deal, announced last week would trade three NMT shares for one Volvere shares. Sandy Jamieson from Volvere's financial advisors, Dawnay, Day, said yesterday the offer was likely to be made well before the 28 days after making the recommended deal, as required under takeover rules.

Volvere, chaired by former Dixons chairman Lord Kalms, says it buys companies which are undervalued or where there is a good prospect of a turnaround.

NMT was once held as the great hope of the Scottish medical devices industry, but its apparently world-beating syringe technology was never produced or sold under licence. Some long-term shareholders have seen more than 90 per cent of their holding disappear.

To delist the company, Volvere would need to acquire either 90 per cent of all capital before it could begin compulsory purchases, or gain support of 75 per cent of the voting capital holders at an EGM. While a number of small shareholders are likely to oppose the move, after previously opposing Volvere chief executive Jonathan Lander's attempt to take control of the company, Volvere is confident of getting the support of most large shareholders.

Shares in NMT and Volvere were both unchanged yesterday at 55.5p and 177.5p respectively.

This article:

Last updated: 19-Sep-06 01:00 BST
Posted at 17/9/2006 05:35 by waldron
NMT shareholders angry at Kalms-led takeover bid by Volvere

PRIVATE shareholders in NMT, the former darling of Scotland's medical technology sector, have reacted angrily to a takeover bid from a group headed by Lord Kalms, the former Dixons chairman.

Volvere, an investment company chaired by Lord Kalms which has a 29.9% stake in NMT, last week offered to acquire the rest of the company in an all-shares deal valued at £5m at last week's prices.

Kalms and Volvere's Jonathan and Nick Lander are already directors of NMT following a toughly fought vote for control last year which left many smaller shareholders suspicious of their motives.

The offer of one Volvere share for every three NMT shares appears to provide a way out for investors in the safety syringe maker, who have seen the value of their holdings dwindle over the past five years. But many would be happier to take a share of NMT's £6m cash pile.

One member of the Interactive Investor internet group wrote: "Volvere shares are tightly held and it is very difficult to deal. Volvere's actual asset value is less than £1.00 a share, so buying NMT at effectively a third of the NMT cash is certainly a great deal for Volvere but pretty awful for NMT - and there is no cash alternative."

Another said: "I am taking advice on whether or not it could be productive to pursue any kind of claim for losses resulting from maladministration."

Although small shareholders hold a majority of NMT's shares, they are unorganised and in many cases demotivated, and have not been able to stand in the way of Volvere's moves. This inertia, which has helped Volvere in the past, may make it more difficult for the investment firm to reach the 90% of acceptances which it requires for a complete takeover.

One investor suggested investors might disrupt Volvere's takeover plans by selling the majority of their shares but holding back a few to entitle them to updates on NMT's activities.

Jonathan Lander previously clashed with NMT shareholder Peter Gyllenhammar, who claimed that Volvere's management was paying itself too much to run a small company with no trading operations.

Volvere's bid was recommended by NMT's independent directors, Lex Gold and George Wardale. Volvere last week said it had an undertaking to accept its offer from Wood Hall Securities, which holds around 16% of NMT shares.

Jonathan Lander said: "Volvere very much looks forward to bringing NMT into the Volvere Group. We believe that this acquisition will offer exciting opportunities for the continued expansion of Volvere's business."

This article:

Last updated: 16-Sep-06 00:58 BST
Posted at 14/9/2006 15:19 by waldron
Volvere agrees to buy NMT Group for 5.3 mln stg in shares

LONDON (AFX) - Volvere PLC said it has agreed to buy the whole of investing
company NMT Group PLC for 5.3 mln stg in shares.
The company said it is offering NMT shareholders 1 new Volvere share for
every three NMT shares.
Based on Volvere's closing price yesterday of 182.5 pence per share, this
values each NMT share at 60.8 pence and the entire company at 5.3 mln stg.
Volvere, who already hold a 29.9 pct stake in NMT, said this represents
around a 20.5 pct premium on NMT's closing share price yesterday of 50.5 pence.
It said it has already had an undertaking to accept the offer from Wood Hall
Securities who hold around 16 pct of NMT shares.
Posted at 16/8/2006 15:21 by wild bill
You were spot on PC, I think they read your comments and posted ASAP!

Holding(s) in Company

RNS Number:7528H
16 August 2006

16 August 2006


The Company Secretary has received notification today from Volvere plc
("Volvere") that Volvere has acquired 1,306,600 Ordinary Shares of GBP4 each in
the Company. Following this transaction Volvere has an interest in 2,604,683
Ordinary Shares in NMT, representing 29.9% of NMT's Ordinary Shares in issue.

NMT also announces that Volvere has today notified the Company that it is no
longer interested in any contract for difference over the Company's Ordinary
shares and that its beneficial interest in the Company is therefore unchanged.

NMT Group plc
Jonathan Lander

0207 7979 7590

This information is provided by RNS
The company news service from the London Stock Exchange

Posted at 05/3/2006 05:39 by waldron
Sun 5 Mar 2006

Lander rejects calls to return £5m NMT cash
JONATHAN Lander, the investor activist who took control of former syringe maker NMT last year, has rejected calls for £5m to be returned to shareholders, and insists he will publish a strategy for the failed business within weeks.

Peter Gyllenhammar, a rival activist who has built up a stake of almost 15% in NMT, last week called for most of the Livingston company's £6m cash pile to be returned to shareholders.

He also accused Lander, his brother Nick and fellow director Lord Kalms of being "unethical" for setting up a potentially lucrative management incentive scheme at NMT.

Speaking to Scotland on Sunday, Lander said NMT's 6,500 shareholders would benefit more if the company's cash pile was reinvested. Most investors have seen the value of their investments collapse since NMT was the darling of the Scottish technology sector in the late 1990s.

He said: "If we do [return cash] the only person that will make any money is Peter Gyllenhammar.

"I think most people want to make some money back. [Gyllenhammar] has only been on the shareholders' register for a few months.

"I invest in technology companies and growth companies. We are trying to get some value out of NMT's assets."

Lander said he had drawn up a strategy for investing NMT's cash pile, which would be sent to shareholders in the next few weeks. "There are just a few people looking at it now," he said.

Lander defended the fee structure which transfers money from NMT to Volvere, which is run by the Landers and Kalms.

He said: "Gyllenhammar calls it unethical, but he means it is disadvantageous for him."

"The fee is £5,000 a month per person, which puts me on £60,000 a year, which is a lot less than I get from other businesses. For me, NMT is a full-time job at the moment."

In addition to that £15,000 monthly fee for three directors, Volvere is entitled to a payment proportionate to any rise in NMT's share price, and further cash if the Landers and Kalms are removed from the board.

The Landers' supporters say the fee structure is necessary to allow them to focus on running the business and reduce the danger that they will be removed suddenly by antagonistic shareholders.

However, Gyllenhammar rejected Lander's plan to invest NMT's cash pile.

He said: "The only thing of interest is what I can do with the 65p per share, or whatever it is, that I am entitled to by my NMT share.

"Do I want the Landers to manage that for a horrendous fee structure, or do I want the money out of the company to invest however I want?

"They are putting the cart before the horse by asking investors to approve the investment plan after they have approved themselves an expensive contract."

Gyllenhammar was initially positive about Volvere, but turned opponent when the company announced its fee structure the day after he raised his stake to 14.6%.

He could combine with private shareholders to call an extraordinary general meeting to oppose the Landers, but said the expense would prevent him from doing so.

This article:

Last updated: 05-Mar-06 00:32 GMT
Posted at 26/2/2006 01:50 by 25october1969
Scotland on Sunday 26th Feb 2006

NMT directors' rewards 'unethical'

PETER Gyllenhammar, the activist investor, has attacked the directors of cash shell company NMT, chaired by former Dixons boss Lord Kalms, as "unethical" and demanded that the former syringe developer return £5m to its shareholders.

Gyllenhammar, who holds just under 15% of NMT, was left fuming after the Livingston company's board approved a fee system which will reward Volvere, a company which shares three directors with NMT. The reward system was announced the day after Gyllenhammar spent around £500,000 to raise his stake in NMT to 14.6%.

Speaking from his base in Sweden, Gyllenhammar said: "This is totally unacceptable. If Volvere had come to me and asked to manage my money, I would have said no. It is not ethical conduct because 70% of shareholders do not have a say."

Gyllenhammar said he had confronted NMT directors Jonathan and Nicholas Lander about the fee structure, which he said could net them millions, but had not received an adequate response.

He said: "I think the best thing would be to cancel this agreement and hand the shareholders all the cash, allowing a small portion, say 10%, to stay in the company to be a vehicle."

The Landers and former Dixons chairman Lord Kalms of Edgware are directors of Volvere, an investor activist company based in London. Lord Kalms' son, Richard, is also a director of Volvere.

The three were elected to the board in place of the previous management team after Volvere took a 26% stake in the company and called an extraordinary general meeting.

NMT, the former darling of Scotland's medical technology sector, has around £6m in cash left over from years of fundraising and restructuring.

Gyllenhammar said the new management fee structure should have been put to shareholders. The precise terms of the agreement have left some investors scratching their heads.

NMT will pay Volvere a monthly fee of 0.25% of its net assets, or around £15,000. Volvere is also entitled to a performance fee equal to 20% of any increase in the company's share price.

If NMT terminates the agreement, Volvere is entitled to 6% of the company's net assets, or around £360,000, plus another unspecified payment based on "the value of an option using the Black Scholes model".

Gyllenhammar said this termination clause would make it expensive for shareholders to follow the example set by the Landers and Kalms by calling an extraordinary general meeting to take control of the company.

He said: "I don't know what to do. This is a complete scandal. If I call for an EGM, there will be significant costs."

Volvere argues that the new fee structure is less expensive for NMT than the previous model. Under that deal, Volvere was entitled to £60,000 per month plus VAT for every month that NMT was subject to a takeover approach.

That structure, introduced on November 26, came to an end on February 9 - two weeks after NMT ended takeover discussions with Zi Medical. In theory, that means that NMT will have to pay Volvere £140,000 including VAT for the two months to January 25.

Shareholders have raised questions over the fact that non-executive directors George Wardale and Lex Gold were said by NMT to have consulted the company's adviser, Shore Capital, and approved the fees agreement. Wardale joined the company just hours before the fee structure was announced.

NMT's shares closed at 57.5p on Friday, down from a peak of 62.5p when the new management fee structure was announced on February 10
Posted at 30/9/2005 08:27 by pc4900074200
From Volvere's Intrim report issued this morning.

Holding in NMT Group PLC

Starting in October 2004 we accumulated a holding of 2,269,024 ordinary shares
of #4 each in NMT Group PLC ("NMT") representing 26.04% of the total issued
ordinary share capital of that company for an aggregate cash consideration of
#1.47m. At the end of the period the investment in NMT was #0.39m (2 July 2004:

NMT is a licensing and development company for safety needle-based medical
devices. For the six months ending 30 June 2005 NMT's interim results showed a
loss before tax of #0.5m on sales of #nil. At that date NMT's net assets
amounted to #6.76m, of which cash represented #6.51m.

In view of NMT's poor financial performance, Volvere requisitioned an
Extraordinary General Meeting of NMT in order to remove that company's board and replace it with executives from Volvere. On 14 September 2005, NMT shareholders voted in support of Volvere's resolutions and your Chairman, Chief Executive and Chief Operating Officer were duly elected to the board of NMT. Since that date Volvere re-financed part of its holding by disposing of 1,306,600 shares in NMT and entering into a long Contract for Difference ("CFD") over the shares sold. The CFD provides us with an economic interest in the share price of the shares sold whilst freeing up cash for other investments. Following the sale Volvere holds 962,424 shares, or 11.05 pct of NMT's issued share capital but with an economic interest in 2,269,024 (26.04%).

At the average price at which the Company acquired its shares (including the
shares subject to the CFD) we consider the shareholding in NMT to represent an
attractive investment opportunity.
We are working hard to maximise the value of this investment and will report on
our progress in due course.

Neometals share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |